Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 653 (1 June 2007) | doi:10.1038/nm0607-653b;
Is it possible to make a Cox-2 inhibitor that's safe?
Abstract
Steve Nissen Chairman, Department of Cardiovascular Medicine Cleveland Clinic Foundation We still don't know if all Cox-2 inhibitors carry a higher risk than all conventional nonsteroidal anti-inflammatory drugs, so the issue of relative risk is still an open question. Donna Arnett Chair, Department of Epidemiology University of Alabama at Birmingham Given the consistent and well documented excess cardiovascular risk associated with Cox-2 inhibitors, and the availability of other anti-inflammatory drugs that do not cause cardiovascular toxicity, what is the motivation for trying to make a new one? Janet Woodcock Deputy commissioner and chief medical officer US Food and Drug Administration No pharmacologically active agent is 'safe'.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).